Credit Suisse Maintains Neutral on Sarepta Therapeutics, Raises Price Target to $100
Credit Suisse analyst Judah Frommer maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Neutral and raises the price target from $75 to $100.
BTIG Maintains Buy on Sarepta Therapeutics, Raises Price Target to $125
BTIG analyst Yun Zhong maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Buy and raises the price target from $110 to $125.
Sarepta’s Duchenne Gene Therapy Shows Sustained Functional Improvements
Sarepta Therapeutics Inc (NASDAQ:SRPT) shared new analyses and functional data from its SRP-9001 development program and the details of Study SRP-9001-301…
Sarepta Therapeutics Says Co’s SRP-9001 Shows Sustained Functional Improvements In Multiple Studies Of Patients With Duchenne
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today shared new analyses and functional data from its SRP-9001 (rAAVrh74.MHCK7.micro-dystrophin) development
Sarepta, Codiak Nix Exosome Therapy Development Pact
Sarepta Therapeutics Inc (NASDAQ:SRPT) notified Codiak BioSciences Inc (NASDAQ:CDAK) that it would terminate the two-year Research License and Option agreement early. The termination…
The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Oct. 7)
The Week Ahead In Biotech (Sept. 19-25): Incyte, Verrica FDA Decisions And Conference Presentations In The Spotlight
Biotech stocks declined for the week ending Sept. 17, extending the losses from the previous week. European Society for Medical Oncology presentations, vaccine news, clinical readouts and IPOs were among the catalysts for the week.
Guggenheim Upgrades Sarepta Therapeutics to Buy
Guggenheim analyst Whitney Ijem upgrades Sarepta Therapeutics (NASDAQ:SRPT) from Neutral to Buy.
Cathie Wood’s ARK Invest Posts Fund Sales For Wednesday, Sept. 8, 2021: TSLA, NVDA, NXPI, LC, TTD, MCRB, CRBU, CLLS, PSTI, SRPT, DRNA, PSTG, NVS, MELI, IRDM, SPR, TRMB, BA
Tesla (TSLA) - 142,708 Shares
Nvidia (NVDA) - 30,225
NXP Semiconductors (NXPI) - 66,507
LendingClub (LC) - 127,719
The Trade Desk (TTD) - 172,095
Seres Therapeutics (MCRB) - 97
Caribou Biosciences (CRBU) -